×
About 15,778 results

ALLMedicine™ Alopecia Center

Research & Reviews  4,175 results

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemot...
https://doi.org/10.1093/oncolo/oyac223
The Oncologist; Liu Y, Fan L et. al.

Nov 26th, 2022 - The anti-tumor activity of nab-paclitaxel followed by epirubicin/cyclophosphamide (EC) as neoadjuvant chemotherapy (NAC) in Asian patients remain unclear, particularly in the aggressive subtype triple-negative breast cancer (TNBC). This study aime...

Advanced thallium toxicity.
https://doi.org/10.1136/pn-2022-003577
Practical Neurology; Zou H, Zou S

Nov 25th, 2022 - Thallium is a highly toxic tasteless, odourless and water-soluble metal that can be absorbed through the skin, inhaled or ingested. Due to the rarity of thallium toxicity, it is frequently misdiagnosed or the diagnosis is delayed. We report a 41-y...

The efficacy of LED microneedle patch on hair growth in mice.
https://doi.org/10.1007/s00403-022-02476-3
Archives of Dermatological Research; Kittigul L, Meephansan J et. al.

Nov 24th, 2022 - Light penetration depth in the scalp is a key limitation of low-level light therapy for the treatment of androgenetic alopecia (AGA). A novel light emitting diode (LED) microneedle patch was designed to achieve greater efficacy by enhancing the pe...

Kikuchi-Fujimoto disease as the initial manifestation of systemic lupus erythematosus c...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682638
BMC Pediatrics; Liu C, Jin Y et. al.

Nov 23rd, 2022 - Kikuchi-Fujimoto disease (KFD) is a self-limiting and benign disease characterized by cervical lymphadenopathy and fever. Although KFD should be made differentially diagnosed from infectious, autoimmune, and malignant diseases, it sometimes occurs...

Laparoscopic Sleeve Gastrectomy in Adolescents: Ten-Years Follow-up.
https://doi.org/10.1007/s11695-022-06348-7
Obesity Surgery; Goldenshluger M, Iluz R et. al.

Nov 23rd, 2022 - Metabolic and bariatric surgery (MBS) has emerged as the most effective treatment for adolescents with severe obesity. Despite the steady increase in frequency of MBS in adolescents, most reports focus on short-term (1-2 years) follow-up. To repor...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  427 results see all →

Clinicaltrials.gov  442 results

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05398809

Oct 14th, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...

Study Evaluating Efficacy of Topical Squaric Acid Dibutyl Ester in Children and Adolescents With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05414266

Oct 13th, 2022 - The purpose of this study is to evaluate the efficacy and tolerability of squaric acid dibutylester (SADBE) in children and adolescents with alopecia areata (AA) and to evaluate effect of squaric acid dibutyl ester on patient-centered outcomes and...

Comparing Aloe Vera Gel and Rosemary Oil in Pressure Injury Prevention
https://clinicaltrials.gov/ct2/show/NCT05578638

Oct 13th, 2022 - Aloe Vera is medicinal plant that has been used to treat skin problems since 1500 BC Many studies have shown that using Aloe Vera to treat various wounds such as psoriasis, mouth ulcers, diabetic ulcers herpes and bed sores has had positive effect...

Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
https://clinicaltrials.gov/ct2/show/NCT02797470

Oct 5th, 2022 - PRIMARY OBJECTIVE: I. Safety, defined as timely engraftment (the collective establishment of a persistent absolute neutrophil count of at least 500 cells/mm^3 and platelet count of 20,000 cells/mm^3 without transfusion for 3 consecutive measuremen...

Use of Botulinum Toxin in the Treatment of Androgenic Alopecia
https://clinicaltrials.gov/ct2/show/NCT05456087

Oct 5th, 2022 - Adult volunteers aged 22-45 years presenting with mild to moderate patterned hair loss will be screened for participation. Twenty subjects (10 males and 10 females) meeting the inclusion/exclusion criteria will be recruited to participate. Prior t...

see more →

News  1,240 results

Belantamab Mafodotin to Be Withdrawn From US Market for Relapsed/Refractory Myeloma
https://www.onclive.com/view/belantamab-mafodotin-to-be-withdrawn-from-us-market-for-relapsed-refractory-myeloma

Nov 22nd, 2022 - GlaxoSmithKline (GSK) plc has initiated the process to withdraw the United States marketing authorization for belantamab mafodotin-blmf (Blenrep) for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at le...

EMA Recommends Limiting the Indications for JAK Inhibitors
https://www.medscape.com/viewarticle/984399

Nov 21st, 2022 - AMSTERDAM — In an effort to minimize the risk of serious side effects associated with Janus kinase (JAK) inhibitors, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended limiting the indicat...

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC
https://www.onclive.com/view/frontline-eganelisib-triplet-provides-potential-long-term-pfs-benefit-in-metastatic-tnbc

Nov 15th, 2022 - The addition of eganelisib (IPI-549) to atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) demonstrated evidence of a long-term progression-free survival (PFS) benefit when used as first-line treatment in patients with metastatic triple-negati...

Immunotherapy and You: Gynecologic Treatment Efficacy From a Patient’s Perspective
https://www.onclive.com/view/immunotherapy-and-you-gynecologic-treatment-efficacy-from-a-patient-s-perspective

Nov 10th, 2022 - In this second episode of OncChats: Immunotherapy and You, John Nakayama, MD, of the Division of Gynecologic Oncology, Allegheny Health Network, and assistant professor of OBGYN at Drexel University, and Ali Amjad, MD, medical hematologic oncologi...

Belantamab Mafodotin Fails to Meet PFS End Point in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/belantamab-mafodotin-fails-to-meet-pfs-end-point-in-relapsed-refractory-multiple-myeloma

Nov 7th, 2022 - Belantamab mafodotin-blmf (Blenrep) did not generate a progression-free survival (PFS) benefit vs the combination of pomalidomide (Pomalyst) plus low-dose dexamethasone, failing to meet the primary end point of the phase 3 DREAMM-3 trial (NCT04162...

see more →

Patient Education  24 results see all →